Alnylam inks deal to commercialize Onpattro in Israel

22 January 2019

RNAi therapeutics Specialist Alnylam Pharmaceuticals (Nasdaq: ALNY) and Israel’s Medison Pharma have entered into an exclusive agreement to commercialize Onpattro (Patisiran), the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio.

The agreement between Alnylam and Medison includes Onpattro, approved in the European Union and the USA in August 2018 for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. It also includes givosiran, a late-stage investigational RNAi therapeutic for the treatment of acute hepatic porphyria (AHP); and lumasiran, a late-stage investigational RNAi therapeutic for the treatment of primary hyperoxaluria Type 1 (PH1). These medicines are not currently approved for use in Israel and givosiran and lumasiran have not yet been approved by any regulatory authority. Financial terms of the collaboration are not disclosed.

Important step in expansion

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK